Wells Fargo’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Wells Fargo’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7	Closed	-$18	–	7761
2024 Q1	$18	Buy	7 +1	+17%	+$3	﹤0.01%	7155
2023 Q4	$22	Hold	6	–	–	﹤0.01%	7190
2023 Q3	$31	Hold	6	–	–	﹤0.01%	7061
2023 Q2	$51	Buy	6 +1	+20%	+$10	﹤0.01%	7049
2023 Q1	$62	Hold	5	–	–	﹤0.01%	7059
2022 Q4	$75	Hold	5	–	–	﹤0.01%	6872
2022 Q3	$0	Buy	5 +3	+150%	+$209	﹤0.01%	7747
2022 Q2	$0	Sell	2 -51	-96%	-$4.36K	﹤0.01%	7843
2022 Q1	$8K	Sell	53 -87	-62%	-$20.1K	﹤0.01%	6368
2021 Q4	$42K	Sell	140 -600	-81%	-$230K	﹤0.01%	6055
2021 Q3	$288K	Buy	740 +738	+36,900%	+$315K	﹤0.01%	4948
2021 Q2	$1K	Buy	+2	New	+$866	﹤0.01%	6794

Other funds holding FNCH

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Wells Fargo's FNCH Position: Q2 2024 in Review

Wells Fargo sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2024, closing a stake of 7 shares — an estimated $18 sold.

Wells Fargo first reported a position in FNCH in Q2 2021 and held it in 12 quarters. The position peaked at $288K in Q3 2021. 1 fund tracked by Wall St. Rank holds FNCH as of Q2 2024.

Wells Fargo reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 7 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2024, an estimated $18.
Wells Fargo first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
Wells Fargo's Finch Therapeutics Group, Inc. Common Stock position peaked at $288K in Q3 2021.
1 fund tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.